Objective Selective progesterone receptor modulators (SPRMs) in women with uterine
fibroids (UFs) reduce heavy menstrual bleeding (HMB) and tumor size. We report the results …

Objectives To assess the safety and efficacy of four vilaprisan doses (0.5–4.0 mg) in women
with uterine fibroids. Design Randomized, double-blind, placebo-controlled, multicenter trial …

Abstract Background Uterine fibroids (UFs) may be treated with progesterone receptor
modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the …

Objective To assess the efficacy of vilaprisan compared with placebo in the management of
the symptoms of uterine fibroids (UF), with a secondary objective to provide a descriptive …

Objective Vilaprisan is a highly potent selective progesterone receptor modulator shown to
reduce heavy menstrual bleeding, induce amenorrhea, and diminish uterine fibroid volume …

Uterine fibroids are benign hormone-sensitive tumors of the uterus that often affect women of
reproductive age. Although many fibroids are asymptomatic, some women experience …

Objective To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg
daily ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. Design …

Introduction: The medical strategy to antagonize myoma size and related-symptoms is to
reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH …

Background: Vilaprisan (VPR) is a new orally available selective progesterone receptor
modulator (SPRM), with anti-proliferative activity against uterine fibroids (UFs). It definitively …

Objective To assess long term safety of extended repeated 3-month courses of ulipristal
acetate (UPA) 10 mg/day, for up to 8 courses, with focus on endometrial and laboratory …